Profile
Kalbe Farma Tbk
Kalbe was incorporated in 1966. In 1991, Kalbe was listed on the Indonesia Stock Exchange as a public company. Kalbe has significantly grown from its humble beginnings as a pharmaceuticals business run from its founder’s garage in North Jakarta. Today Kalbe has become the largest publicly-listed pharmaceuticals company in Southeast Asia, with a market capitalization of USD3.9 billion and a sales turnover of Rp10.91 trillion as of the end of 2011.
Kalbe has focused its business on four divisions: prescription pharmaceuticals, consumer health products, nutritionals, and distribution and logistics. Supported by over 15,000 employees, inclusive of 4,000 sales and marketing professionals covering the entire Indonesian archipelago, Kalbe maintains coverage of more than 70% of general practitioners, 90% of specialists, 100% of hospitals, 100% of pharmacies across Indonesia for the prescription pharmaceuticals market and 80% for the consumer health and nutritionals markets.
Innovation remains as the spirit that characterizes every stage of growth for Kalbe, as it has metamorphosed into the largest pharmaceutical company in Indonesia. Research and development for new products that are innovative, high-value, and appropriately addressing the needs of society with good prospects in the future continues to take place. In recognition of the reality that Indonesia is a vast archipelago, Kalbe continues to increase both the capacity and quality of its distribution services. Continuous improvement of its supply chain integration is among the main concerns of Kalbe in improving efficiency and cash flows of the Company.
After 4 decades of growth, Kalbe has transformed itself from a pharmaceuticals manufacturer into a provider of “comprehensive healthcare solutions”, through offering a range of comprehensive health care solution products that goes from pharmaceuticals, nutrition, supplements, health foods and beverages to medical devices, including primary healthcare services. Through conducting comprehensive (or holistic) care for consumers, Kalbe is able to maintain and enhance its business competitiveness amid increasingly fierce competition, fortifying its competitive advantage for the future. It is our target to build global brands with high sales potential in every business unit, to support performance growth.
Maintaining sustainable growth through business unit synergy is Kalbe’s hope in the journey to realize the Company’s mission to improve health for a better life. With the support of quality human resources and through continuous improvement efforts in various business processes, Kalbe is optimistic that it will be able to achieve the Company’s vision “to be the best Indonesian healthcare company, driven by innovation, strong brands and excellent management”.
| Security Code | : | KLBF |
| Office Address | : | Gedung KALBE Let.Jend Suprato Kav. 4 Jakarta |
| Mail Address | : | info@kalbe.co.id |
| Phone | : | 42873888 |
| Fax | : | 42873680 |
| NPWP | : | 01.001.836.4-092.000 |
| NPKP | : | - |
| Website | : | www.kalbe.co.id |
| Listing Date | : | 30-Jul-1991 |
| Board | : | Primary |
| Main Bussiness | : | Pharmacy |
| Sector | : | CONSUMER GOODS INDUSTRY |
| Sub Sector | : | PHARMACEUTICALS |
| Stock Administration Berrau | : | PT Adimitra Transferindo |
Ownership
Shareholders
| Shareholders Name | Shareholders Type | Number of Share | Percentage |
|---|---|---|---|
| Bina Artha Charisma, PT | More Than 5% | 4060816540 | 8 % |
| Gira Sole Prima, PT | More Than 5% | 4767872885 | 9.39 % |
| Ladang Ira Panen, PT | More Than 5% | 4322952940 | 8.51 % |
| Lucasta Murni Cemerlang, PT | More Than 5% | 4439895440 | 8.74 % |
| Diptanala Bahana, PT | More Than 5% | 4447970440 | 8.76 % |
| Santa Seha Sanadi, PT | More Than 5% | 4509646840 | 8.88 % |
| Kalbe Farma Tbk, PT | More Than 5% | 3904950000 | 7.69 % |
| B. R. Irawati Setiady | Director | 4372500 | 0.01 % |
| Public | Less Than 5% | 20325967025 | 40.03 % |
Key Executive
Director :
| Director’s Name | Director’s Position | Independent |
|---|---|---|
| Bernadette Ruth Irawati Setiady | President Director | No |
| Herman Widjaja | Director | No |
| Ongkie Tedjasurja | Director | No |
| Budi Dharma Wreksoatmodjo | Director | No |
| Vidjongtius | Director | Yes |
Commissioners :
| Commissioner’s Name | Commissioner’s Position | Independent |
|---|---|---|
| Johannes Setijono | President Commissioner | No |
| Farid Anfasa Moeloek | Commissioner | Yes |
| Jozef Darmawan Angkasa | Commissioner | No |
| Wahjudi Prakarsa | Commissioner | Yes |
| Santoso Oen | Commissioner | No |
| Ferdinand Aryanto | Commissioner | No |
